Loading…
Loading…
MDBH does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDBH and 80,000+ other tickers.
See exactly how MDBH's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDBH and 80,000+ other tickers.
MDB Capital Holdings, LLC functions primarily as a broker-dealer through its subsidiary operations. The company's activities are divided into two main areas: Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service division provides comprehensive broker-dealer services, focusing on arranging private and public securities offerings, and furnishing research for investment banking due diligence. Meanwhile, the Technology Development division is engaged in the advancement of synthetic biology technology. MDB Capital Holdings, LLC was established in 1997 and is based in Addison, Texas.
Dallas, TX, July 02, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced the publication of a new article in its IP Legal Insights section, continuing the firm's commitment to providing practical legal guidance on the technologies and legal developments reshaping intellectual property.
Dallas, TX, June 30, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announced the release of its latest PatentVest Pulse report, "The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1."
The new PatentVest Pulse report examines how FGF21 is emerging as the next strategic cardiometabolic layer beyond GLP-1, reshaping obesity therapeutics, pharmaceutical partnerships, and intellectual property strategy The report analyzes more than $10. 7 billion in recent acquisitions and licensing activity, highlighting how leading pharmaceutical companies are positioning themselves for the next phase of obesity innovation Dallas, TX, June 30, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announced the release of its latest PatentVest Pulse report, "The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1.
PatentVest Will Discuss Intellectual Property Strategy, Innovation Intelligence, and the Future of AI-Native IP Services PatentVest Will Discuss Intellectual Property Strategy, Innovation Intelligence, and the Future of AI-Native IP Services
• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes • PatentVest's report reveals how combination therapy IP, body-composition optimization, and strategic acquisitions may shape the next phase of obesity therapeutics Dallas, Texas, June 04, 2026 (GLOBE NEWSWIRE) -- Today, PatentVest, a leading provider of IP Strategy and IP Law services, announces the release of its latest report, "The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity" This comprehensive study provides a strategic analysis of the emerging muscle-preservation category developing alongside obesity therapies.